Aspen Pharmacare Debt-Free: Strategic Shift To GLP-1 Injectables
Aspen Pharmacare Debt-Free marks a pivotal moment in its history as it shifts focus toward GLP-1 injectables like semaglutide.
Eli Lilly 2026 Guidance Signals Momentum In Obesity Care
Eli Lilly has forecast 2026 profit and revenue above Wall Street expectations, reinforcing how fast the obesity market is reshaping Big Pharma growth plans. The recent Eli Lilly 2026 Guidance reflects the company’s confidence in strong future performance. The company also beat estimates for fourth-quarter earnings, helped by strong demand for its injectable weight-loss and…...
Roche CT-388 Obesity Drug Posts 22.5% Weight Loss
Roche CT-388 Obesity Drug shows up to 22.5% placebo-adjusted weight loss at 48 weeks, as Roche moves into Phase 3 to challenge Lilly and Novo.
Aspen APAC Divestment Unlocks R26.5 Billion For GLP-1 Focus
Aspen APAC divestment unlocks R26.5bn in capital, sharpening the group’s focus on GLP-1 injectables and reducing net debt heading into 2026.
GLP-1 Weight Loss Drugs Reshape Obesity Care In South Africa
GLP-1 weight loss drugs like Mounjaro and Wegovy are transforming obesity treatment in SA amid rising health concerns and systemic barriers.
Lilly Hits $1 Trillion Valuation with Weight-Loss Success
Eli Lilly hits $1 trillion valuation, marking a historic milestone in the pharmaceutical industry with successful weight-loss drugs.
Aspen Targets Mounjaro Expansion in Africa Following Approval
Aspen's Mounjaro expansion plans promise to enhance diabetes and weight management treatment in Sub-Saharan Africa soon.
Aspen Boosted by Mounjaro: A New Era in Weight Loss
Aspen shares soar following the approval of Mounjaro for weight loss in South Africa. Discover the impact on obesity management.
Cheaper Weight-Loss Drugs for Global Health Needs
… Membership Required You must be a member to access this content.View Membership LevelsAlready a member? Log in here...
Aspen Unlocking Value with New Manufacturing Strategies
Understand Aspen Unlocking Value efforts as CEO Stephen Saad addresses the decline in share price and targets business improvements.